BriaCell Therapeutics Joins MSK's 2025 Therapeutics Accelerator Program
ByAinvest
Thursday, Aug 14, 2025 8:35 pm ET1min read
BCTX--
As one of the world’s foremost cancer research and treatment institutions, MSK offers over 135 years of leadership in patient care, education, and discovery. The MSK Therapeutics Accelerator Cohort program provides BriaCell with access to MSK’s expertise and institutional resources, including Good Manufacturing Practice (GMP) manufacturing services, Investigational New Drug (IND) Application preparation and submission, and regulatory strategy support.
“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, added, “We are excited to welcome BriaCell into the cohort program.”
Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, expressed optimism about the potential of Bria-OTS+ to transform cancer care, stating, “Our participation in this cohort program is yet another step towards achieving that vision.”
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s latest financial position and technical indicators present challenges, but recent corporate developments, including this collaboration with MSK, offer potential upside.
References:
[1] https://www.biospace.com/press-releases/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer
[2] https://drug-dev.com/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer/
BriaCell Therapeutics has been selected for Memorial Sloan Kettering Cancer Center's 2025 Therapeutics Accelerator Program to advance Bria-OTS+ immunotherapy development. The collaboration aims to accelerate development and regulatory processes for the cancer treatment. Despite a challenging financial position and mixed technical indicators, recent corporate developments provide potential upside.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) has been selected for Memorial Sloan Kettering Cancer Center’s (MSK) 2025 Therapeutics Accelerator Program, aiming to accelerate the clinical development of Bria-OTS+, the company’s next-generation personalized off-the-shelf immunotherapy. This collaboration is intended to expedite Bria-OTS+ development for multiple cancer indications, including metastatic breast cancer and prostate cancer.As one of the world’s foremost cancer research and treatment institutions, MSK offers over 135 years of leadership in patient care, education, and discovery. The MSK Therapeutics Accelerator Cohort program provides BriaCell with access to MSK’s expertise and institutional resources, including Good Manufacturing Practice (GMP) manufacturing services, Investigational New Drug (IND) Application preparation and submission, and regulatory strategy support.
“We are honored to work with the scientific and clinical experts at MSK Therapeutics Accelerator,” stated Dr. William V. Williams, BriaCell’s President and CEO. “MSK’s deep expertise in cancer therapy development and state-of-the-art resources make it an ideal partner to accelerate our personalized off-the-shelf immunotherapy platform.”
Eileen Flowers, PhD, Director of Technology Development & Licensing in the Office of Entrepreneurship and Commercialization at MSK, added, “We are excited to welcome BriaCell into the cohort program.”
Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer, expressed optimism about the potential of Bria-OTS+ to transform cancer care, stating, “Our participation in this cohort program is yet another step towards achieving that vision.”
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company’s latest financial position and technical indicators present challenges, but recent corporate developments, including this collaboration with MSK, offer potential upside.
References:
[1] https://www.biospace.com/press-releases/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer
[2] https://drug-dev.com/briacell-selected-for-msks-2025-therapeutics-accelerator-program-for-bria-ots-for-cancer/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet